Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 3, 2019 - Issue 1
Journal homepage
131
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Lymphoproliferative disease in a patient with Takayasu arteritis and ulcerative colitis

Yosuke AsanoDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0001-5261-5275View further author information
ORCID Icon,
Ken-Ei SadaDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-1020-0818View further author information
ORCID Icon,
Keigo HayashiDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0002-2935-6284View further author information
ORCID Icon,
Yuriko YamamuraDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0002-9566-244XView further author information
ORCID Icon,
Sumie HiramatsuDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0003-2653-9592View further author information
ORCID Icon,
Keiji OhashiDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0001-8004-1563View further author information
ORCID Icon,
Yoshia MiyawakiDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0002-6981-3443View further author information
ORCID Icon,
Michiko MorishitaDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0001-8939-4816View further author information
ORCID Icon,
Haruki WatanabeDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0001-7837-086XView further author information
ORCID Icon,
Yoshinori MatsumotoDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0001-7047-2976View further author information
ORCID Icon,
Tomoko KawabataDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0001-9450-2703View further author information
ORCID Icon,
Noriyuki TanakaDepartment of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; View further author information
,
Sakiko HiraokaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JapanView further author information
&
Jun WadaDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ORCID Iconhttp://orcid.org/0000-0003-1468-5170View further author information
ORCID Icon show all
Pages 34-37 | Received 18 May 2018, Accepted 30 Jul 2018, Published online: 03 Sep 2018

References

  • Terao C, Matsumura T, Yoshifuji H, et al. Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap. Arthritis Rheumatol. 2015;67:2226–2232.
  • Gaulard P, Swerdlow SH, Harris NL, et al: Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. p. 350–351.
  • Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.
  • Bagg A. Therapy-associated lymphoid proliferations. Adv Anat Pathol. 2011;18:199–205.
  • Murakami K, Ohsawa M, Hu SX, et al. Large-vessel arteritis associated with chronic active Epstein-Barr virus infection. Arthritis Rheum. 1998;41:369–373.
  • Dayharsh GA, Loftus EV Jr., Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72–77.
  • Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063–2071.
  • Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145:1007–1015 e3.
  • Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977.
  • Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012;71:75–79.
  • Thompson G, Pepperell D, Lawrence I, et al. Crohn's disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab. BMJ Case Rep. 2017;2017.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.